Dendreon CFO bails for job at StemCells; India's Sun Pharma raises growth forecast to 25%;

@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma

@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce

@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce

> Dendreon ($DNDN) CFO Greg Schiffman has jumped ship to StemCells, where he will take over as CFO and executive vice president of finance. Release

> India's Sun Pharma hiked its outlook for fiscal 2014 revenue growth to 25% from its previously forecast 18-20%; its quarterly net sales grew by 58% to 41.92 billion rupees, or $664 million. Report

> Despite an extended period of shutdowns and cutbacks in the region, drugmakers still account for a $26.6 billion boost to the New Jersey economy. Report

> India's Strides Arcolab saw third-quarter profits slump because of foreign exchange losses and regulatory delays, but the company stuck to its forecast for the year. Report

> Novartis' ($NVS) generics unit Sandoz recalled a mispackaged batch of tuberculosis drugs from 5 states in India. Report

> The Slovenian drugmaker Krka posted a 12% increase in profits for the first 9 months of the year, to $1.67 million. Report

Medical Device News

@FierceMedDev: Analysts: Volcano could be an M&A fit for Abbott, Medtronic. More | Follow @FierceMedDev

@MarkHFierce: Inspired by a wine cork removal device, an Argentinian mechanic developed a surgical tool to aid difficult births. Story | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery: DNA-delivering patch spurs bone growth. Piece | Follow @MichaelGFierce

> Tandem banks $120M in topped-out IPO, stirring med tech market hopes. Article

> Biomet hit with metal hip lawsuit in Canada. More

Biotech News

@FierceBiotech: Merck KGaA says big M&A could jump-start stilted pipeline. Story | Follow @FierceBiotech

@JohnCFierce: Best case scenario for Lemtrada: FDA OKs for a very limited group of desperate patients. | Follow @JohnCFierce

@DamianFierce: Sanofi gets mixed FDA blessing for MS drug Lemtrada. More | Follow @DamianFierce

@EmilyMFierce: Tuberculosis R&D dropped by $30.4 million in 2012 compared with 2011. Report | Follow @EmilyMFierce

> Trio of IPO setbacks strike sour note at biotech's Wall Street party. News

> Novartis, Novavax whip up new bird flu vaccines as pandemic fears flourish. Article

> Theravance scraps ADHD program after drug flunks PhII study. More

Vaccines News

> Agenus, Sanofi-NIH collaboration race to develop genital herpes vaccine. Story

> Novartis to sell first piece of vaccine unit in $1.7B deal. Article

> Polio outbreak sparks fears refugees will carry virus to Europe. Report

> Dendreon to lay off more staff as Provenge disappoints. Again. More

> Novavax presents positive Phase I data for H7N9 vaccine. Story

> U.K. adds schools to flu data-gathering project. Item

Pharma Manufacturing News

> Track-and-trace bill may be finished this week. Article

> Lilly to invest $700M in plant expansions. More

> Sandoz pulls some TB drugs in India. Report

> Dendreon hopes manufacturing can save the day. Story

> FDA red-flags dangerous counterfeit ED product. Article

> New manufacturing processes could produce bird flu vax ASAP. Item

And Finally... Diabetes now kills one person every 6 seconds and affects 382 million people worldwide. Report

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

AstraZeneca has signed into the EU’s first finalized COVID-19 vaccine supply agreement.  

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.